Navigation Links
Aspirin surpasses Modern Anti-clotting Drugs

Aspirin has been a pain-reliever for more than 100 years. And while most of the popular remedies used in the 19th century have been abandoned, the use of aspirin has increased. This powerful pill will //reduce pain, fever, inflammation, prevent blood clots, and even reduce the risk of heart attacks and stroke.

In the more than 35 years since aspirin's potent anti-clotting effects were first discovered, relatively few drugs have been developed that can even be compared to the efficacy, ease of use, and price of aspirin. From the meta-analyses, and to many stroke experts and biostatisticians in this field, aspirin remains the drug of choice.

Extensive advertising has been promoting three other prescription drugs, also platelet inhibitors, which have similar anti-clotting effects. They are: ticlopidine (Ticlid), clopidogrel (Plavix), and dipyridamole with very small doses of aspirin (Aggrenox). Ticlopidine's use is now known to have been associated with at least 260 deaths from blood disorders. Because of this danger, Ticlopidine is no longer recommended by many physicians, but is still on the market.

Evaluation of Plavix in a single large trial with stroke patients was not significantly better than aspirin in reducing further strokes, and the company has twice been cautioned by the FDA not to promote the drug. Finally, the British Medical Journal concluded that addition of dipyridamole to aspirin produced no significant further reduction in vascular events compared with aspirin alone.

Page: 1

Related medicine news :

1. What happens when Asthmatics consume Aspirin?
2. Aspirin reduces deaths
3. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
4. Aspirin - a drug after one’s own hear
5. Aspirin deflated
6. Night Time Aspirin Regimen Found to Reduce Blood Pressure
7. Aspirin Lowers Leukemia Risk
8. Aspirin usage linked with pancreatic cancer
9. Aspirin Found To Reduce The Risk Of Colon Cancer
10. Aspirin Induced Asthma , A Little-Known Inducer
11. Aspirin Found To Be Effective In Reducing Breast Cancer Rates
Post Your Comments:

(Date:11/30/2015)... ... November 30, 2015 , ... ... Centers’ National Poison Data System (NPDS) reveals that in 2014, someone called a ... cases, over two million of which were human exposure cases. , The American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
Breaking Medicine Technology: